New medical breakthroughs are altering how diseases are treated in ways that seemed unimaginable just a decade ago。 Perhaps one of the most significant developments is the advent of new gene therapies and drugs that boost the immune system’s ability to target tumor cells。 But we recognize that progress across different therapeutic areas has been uneven, including for complex neurological diseases。 In part, this is because the underlying causes of severe neurological diseases may not be as well understood compared to ailments like cancer。 The brain, in many respects, is the last organ system where many aspects of our understanding of the underlying biology of disease remain uncertain。
Symptoms and progression of neurological diseases can also vary significantly across patients, and even within patients, and across organ systems. Some diseases, like Alzheimer’s, may progress invisibly for years. Once clinical symptoms become apparent, significant function may already be lost. These issues can make drug development more challenging for companies, and are deeply frustrating for patients and caregivers living with these serious and life-threatening conditions.
The FDA recognizes the urgent need for new medical treatments for many serious conditions including neurological disorders such as muscular dystrophies, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), migraine and epilepsy. This requires us to become more nimble, collaborative and patient-focused. As part of our ongoing efforts to expand access to safe and effective treatment options across all disease areas and promote innovation, the FDA is modernizing multiple aspects of our drug regulatory programs – including how we communicate scientific and regulatory guidance for drug development.
To keep pace with science and best meet the needs of the patients we serve, we’re also changing how we organize ourselves as part of the medical product review process – moving away from a more siloed structure that had people working in discrete organizational units. Professionals with particular subject matter expertise often operated as independent entities based on their areas of experience. Instead, we’re moving toward a more team-based approach as part of our Center for Drug Evaluation and Research’s (CDER) Office of New Drugs modernization. Under this team-based approach, experts across different fields will share best practices and knowledge focused on diseases. This approach will integrate people from different disciplines – such as pharmacology and statistics - and across different stages of the life cycle of a product from the pre- and post-market phases who are all working toward a common public health goal.
One area where we’re already putting this new organization to the test is through guidance development. We’re piloting a new, streamlined process for writing science-based, practical guidance documents and getting them out more quickly. Guidances in the pilot are intended to be concise and free of lengthy narratives that didn’t help advance the goals of providing clear scientific feedback. These new guidances should not duplicate information already available in other documents.
Today I’m pleased to issue five guidance documents that benefited from the streamlined approach of this pilot as part of a broader, programmatic focus on advancing treatments for neurological disorders that aren’t adequately addressed by available therapies. These guidance documents provide details on how researchers can best approach drug development for certain neurological conditions – Duchenne muscular dystrophy (DMD) and closely related conditions, migraine, epilepsy, AD and ALS. These guidance documents provide our current thinking and sound regulatory and scientific advice for product developers so that safe and effective treatments can ultimately be made available to patients. These documents are each a culmination of thoughtful scientific collaboration within the agency and incorporate important input from patients, researchers and advocates. We hope that providing up-to-date, clear information about our scientific expectations, such as clinical trial design and ways to measure effectiveness, will save companies time and resources and ultimately, bring effective new medicines to patients more efficiently.
These disease-oriented drug development guidances are an example of the strategies we’re implementing under the leadership of CDER’s director, Dr。 Janet Woodcock, to modernize the agency’s new drug program。
The guidances also signal how modernization of the new drug regulatory program includes an enhanced focus on incorporation of patient input into our thinking. While the agency engages with patients on many fronts, this set of guidances showcases unique involvement from patient communities in collaborating with the FDA to make sure patient voices are heard. We will continue this type of partnership.
For example, the newly finalized Guidance for Industry was preceded by a pioneering effort from Parent Project Muscular Dystrophy who, in 2014, submitted their own independent that provided important scientific and patient input from the DMD community. It helped inform the FDA’s development of both our own draft guidance and the final version issued today.
Another example is the new ALS-related guidance, Despite the availability of some approved therapies, there is an urgent need to identify additional effective treatments for patients with ALS。 We’ve been honored to work with the ALS Association to advance these goals。 The ALS Association put together a comprehensive , funded by the famous “ice bucket challenge.” This proposed draft guidance, in turn, provided the FDA with scientific advice and insight into the disease that helped us advance our own draft guidance that provides our clear thinking on drug development in this area.
Another guidance of note that we’ve issued today is the revised The FDA has been working closely with patients and the scientific community to gain the knowledge that will support intervention in very early AD in ways that have the potential to stop the disease before it causes clinical problems. This document describes innovative approaches to studying very early disease before the onset of dementia, including strategies for trials incorporating patients with Alzheimer’s who haven’t experienced any visible impairment (in the form of cognitive or functional deficits), but who may be identified through the use of sensitive cognitive screening, imaging tests, or biomarkers.